Lymphoma

P=N/A, N=40, Recruiting, University of Utah

P1, N=50, Recruiting, FBD Biologics Limited | Trial completion date: Aug 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026

P3, N=150, Not yet recruiting, CStone Pharmaceuticals | Trial completion date: Jun 2029 --> Dec 2029 | Trial primary completion date: Jun 2028 --> Dec 2028

P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027

P1/2, N=274, Active, not recruiting, Galapagos NV | Recruiting --> Active, not recruiting

Strikingly, the addition of PD1 alone or the PD1 plus CTLA4 doublet to low-dose 211At-hCD20 significantly strengthened suppression of both tumors and increased mouse survival. Future translation of this synergistic combination of α-radiotherapy and immune checkpoint inhibition holds promise for the treatment of high-risk aggressive lymphomas, including cases with postinduction minimal residual disease or antigen loss after targeted therapies.

P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66

P=N/A, N=20, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Jan 2026 --> Apr 2026

P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P1, N=20, Not yet recruiting, National Cancer Institute (NCI)

In the Ehrlich ascites carcinoma (EAC) model, oral administration of EEJB (400 mg/kg) significantly reduced tumor volume, packed cell volume, and viable cell count, extended mean survival time, and ameliorated tumor-induced hematological and hepatic alterations. These findings position J. betonica L. as a promising plant-derived, multi-target anticancer candidate, meriting further isolation of active principles and mechanistic exploration.

Given the favorable toxicity profile of mosunetuzumab, and rapid and durable complete responses observed in this cohort, further investigation of mosunetuzumab for the treatment of RT, as monotherapy and in combination with other novel agents or chemotherapy, is warranted. NCT02500407.